Search

Your search keyword '"Non-invasive serum biomarkers"' showing total 5 results
Start Over Descriptor "Non-invasive serum biomarkers"
5 results on '"Non-invasive serum biomarkers"'

1. The non-invasive serum biomarkers contributes to indicate liver fibrosis staging and evaluate the progress of chronic hepatitis B

Author

Shaoxiong Zeng, Zhenzhen Liu, Bilun Ke, Yiwang Zhang, Qian Wang, and Siwei Tan

Subjects
Chronic hepatitis B, Liver fibrosis, Liver cirrhosis, Liver biopsy, Non-invasive serum biomarkers, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background This study aimed to evaluate the diagnostic abilities of the non-invasive serum biomarkers to predict liver fibrosis staging and evaluate the progress of hepatitis B. Methods We enrolled 433 patients with chronic HBV infection had complete medical data available for the study, who underwent percutaneous liver biopsy. The extent of fibrosis was assessed using the modified METAVIR score. The predictive values of the non-invasive serum biomarkers were evaluated by the areas under the receiving operator characteristics curves (AUROCs) with 95% confidence intervals. Results The proportion of males with progressive stages of liver fibrosis was relatively larger, and the average age of patients with cirrhosis stages is older than the non-cirrhotic stages. We found PLT, GGT, ALP, TB, FIB4 and GPR to be significantly associated with liver fibrosis in our cohort. GGT showed a sensitivity of 71.4% and specificity of 76.7% in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3), with an AUROC of 0.775 (95%CI 0.711–0.840).The AUROCs of the GPR in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3) was 0.794 (95%CI 0.734–0.853), but it had a lower sensitivity of 59.2%. Additionally, GGT, FIB4, and GPR could differentiate advanced fibrosis (F3-4) from non-advanced fibrosis (F1-2) among individuals with chronic hepatitis B, with AUROCs of 0.723 (95%CI 0.668–0.777), 0.729 (95%CI 0.675–0.782), and 0.760 (95%CI: 0.709–0.811) respectively. Conclusions GGT was a better biomarker to distinguish cirrhosis (F4) from non-cirrhotic stages (F1-3), while GPR was a better biomarker to identify advanced fibrosis (F3-4) and non-advanced fibrosis (F1-2) in patients with chronic hepatitis B.

Published
2024
Full Text
View/download PDF

2. The non-invasive serum biomarkers contributes to indicate liver fibrosis staging and evaluate the progress of chronic hepatitis B.

Author

Zeng, Shaoxiong, Liu, Zhenzhen, Ke, Bilun, Zhang, Yiwang, Wang, Qian, and Tan, Siwei

Subjects
HEPATIC fibrosis, CHRONIC hepatitis B, BIOMARKERS, HEPATITIS B, LIVER biopsy
Abstract

Background: This study aimed to evaluate the diagnostic abilities of the non-invasive serum biomarkers to predict liver fibrosis staging and evaluate the progress of hepatitis B. Methods: We enrolled 433 patients with chronic HBV infection had complete medical data available for the study, who underwent percutaneous liver biopsy. The extent of fibrosis was assessed using the modified METAVIR score. The predictive values of the non-invasive serum biomarkers were evaluated by the areas under the receiving operator characteristics curves (AUROCs) with 95% confidence intervals. Results: The proportion of males with progressive stages of liver fibrosis was relatively larger, and the average age of patients with cirrhosis stages is older than the non-cirrhotic stages. We found PLT, GGT, ALP, TB, FIB4 and GPR to be significantly associated with liver fibrosis in our cohort. GGT showed a sensitivity of 71.4% and specificity of 76.7% in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3), with an AUROC of 0.775 (95%CI 0.711–0.840).The AUROCs of the GPR in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3) was 0.794 (95%CI 0.734–0.853), but it had a lower sensitivity of 59.2%. Additionally, GGT, FIB4, and GPR could differentiate advanced fibrosis (F3-4) from non-advanced fibrosis (F1-2) among individuals with chronic hepatitis B, with AUROCs of 0.723 (95%CI 0.668–0.777), 0.729 (95%CI 0.675–0.782), and 0.760 (95%CI: 0.709–0.811) respectively. Conclusions: GGT was a better biomarker to distinguish cirrhosis (F4) from non-cirrhotic stages (F1-3), while GPR was a better biomarker to identify advanced fibrosis (F3-4) and non-advanced fibrosis (F1-2) in patients with chronic hepatitis B. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study

Author

Nuri Beslen, Hüseyin Tarakçı, Ali Kaya, Tuna Demirdal, Sami Kinikli, Seda Erdoğan, Sıla Akhan, Gürdal Yilmaz, Huseyin Turgut, Fatih Ozdener, Rahmet Guner, Ziya Kuruüzüm, Özcan Aydoğdu, Ahmet Ali Gökal, Özgür Dağlı, Iftihar Koksal, Mehmet Candan, Mehmet Parlak, Yunus Gürbüz, and Giresun Üniversitesi

Subjects
Liver Cirrhosis, Male, Turkey, clinical evaluation, Biopsy, Hepacivirus, medicine.disease_cause, Gastroenterology, Turkey (republic), FibroTest, 0302 clinical medicine, aspartate aminotransferase, Liver Function Tests, Fibrosis, middle aged, statistics and numerical data, APRI, liver fibrosis, medicine.diagnostic_test, biology, Forns index, Fib-4, adult, Area under the curve, clinical trial, Alanine Transaminase, Hepatitis C, biological marker, virology, aged, female, Liver, 030220 oncology & carcinogenesis, Liver biopsy, Area Under Curve, young adult, 030211 gastroenterology & hepatology, diagnostic value, medicine.medical_specialty, Adolescent, area under the curve, Hepatitis C virus, alanine aminotransferase, disease classification, complication, Sensitivity and Specificity, Article, 03 medical and health sciences, open study, blood, turkey (bird), Internal medicine, medicine, chronic hepatitis C, Humans, Non-invasive serum biomarkers, liver function test, human, procedures, Aspartate Aminotransferases, liver biopsy, business.industry, Platelet Count, scoring system, Hepatitis C, Chronic, medicine.disease, major clinical study, Chronic hepatitis C infection, human tissue, multicenter study, Alanine transaminase, biology.protein, observational study, pathology, business, Liver function tests, aspartate aminotransferase blood level, Biomarkers
Abstract

demirdal, tuna/0000-0002-9046-5666 WOS: 000440301200015 PubMed: 30249562 Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold standard for assessment of fibrosis but this procedure is an invasive procedure. We aimed to evaluate the diagnostic efficiency of non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients. Materials and Methods: Two hundred and sixteen treatment-naive CHC patients were enrolled from 32 locations across Turkey in this open-labelled, non-interventional prospective observational study. FibroTest (R), aspartate aminotransferase-to-platelet ratio index(A-PRI), aspartate aminotransferase and alanine aminotransferase ratio (AAR), fibrosis index based on four factors (FIB-4), Age-platelet(AP) index and Forns index were measured and compared with Metavir scores got from liver biopsies. Results: Data from 182 patients with baseline liver biopsy were suitable for analysis. One hundred and twenty patients (65.9%) had F0-F1 fibrosis and 62 patients (34.1%) had F2-F4 fibrosis. APRI 0.732 area under the curve(AUC) indicated advanced fibrosis with 69% sensitivity and 77% specificity. FIB-4 0.732 AUC and FibroTest 0.715 AUC indicated advanced fibrosis with 69% and 78.4% sensitivity, and 75% and 71.4% specificity, respectively. The combined use of tests also led to an increase in AUC and specificity. Combinations of FibroTest with APRI and/or FIB-4, and FIB-4 with APRI were optimal for the evaluation of liver fibrosis. Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further. Roche PharmaceuticalsRoche Holding [ML21920] This study was financially supported by Roche Pharmaceuticals (Protocol No: ML21920).

Published
2018

4. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study

Author

Köksal, I., Yilmaz, G., Parlak, M., Demirdal, T., Kinikli, S., Candan, M., Kaya, A., Akhan, S., Aydoǧdu, Ö., Turgut, Hüseyin, Gürbüz, Y., Daǧli, Ö., Gökal, A.A., Güner, R., Kuruüzüm, Z., Tarakçi, H., Beslen, N., Erdoǧan, S., Özdener, F., Duyar, E., Inan, D., Leblebicioǧlu, H., Sehmen, E., Yuluǧkural, Z., Namiduru, M., Kökoǧlu, Ö.F., Baykam, N., Ural, O., Bostanci, F., Kaya, S., Kiliç, S., Önlen, Y., Özdemir, D., Tabak, F., and Yamazhan, T.

Subjects
Liver Cirrhosis, Male, Turkey, clinical evaluation, Biopsy, Hepacivirus, Turkey (republic), FibroTest, aspartate aminotransferase, Liver Function Tests, middle aged, statistics and numerical data, APRI, liver fibrosis, Forns index, Fib-4, adult, clinical trial, Alanine Transaminase, biological marker, virology, aged, female, Liver, Area Under Curve, young adult, diagnostic value, Adolescent, area under the curve, alanine aminotransferase, disease classification, complication, Sensitivity and Specificity, Article, open study, blood, turkey (bird), chronic hepatitis C, Humans, Non-invasive serum biomarkers, liver function test, human, procedures, Aspartate Aminotransferases, liver biopsy, Platelet Count, scoring system, Hepatitis C, Chronic, major clinical study, Chronic hepatitis C infection, human tissue, multicenter study, observational study, pathology, aspartate aminotransferase blood level, Biomarkers
Abstract

Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold standard for assessment of fibrosis but this procedure is an invasive procedure. We aimed to evaluate the diagnostic efficiency of non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients. Materials and Methods: Two hundred and sixteen treatment-naive CHC patients were enrolled from 32 locations across Turkey in this open-labelled, non-interventional prospective observational study. FibroTest®, aspartate aminotransferase-to-platelet ratio index(APRI), aspartate aminotransferase and alanine aminotransferase ratio (AAR), fibrosis index based on four factors (FIB-4), Age-platelet(AP) index and Forns index were measured and compared with Metavir scores got from liver biopsies. Results: Data from 182 patients with baseline liver biopsy were suitable for analysis. One hundred and twenty patients (65.9%) had F0-F1 fibrosis and 62 patients (34.1%) had F2-F4 fibrosis. APRI 0.732 area under the curve(AUC) indicated advanced fibrosis with 69% sensitivity and 77% specificity. FIB-4 0.732 AUC and FibroTest 0.715 AUC indicated advanced fibrosis with 69% and 78.4% sensitivity, and 75% and 71.4% specificity, respectively. The combined use of tests also led to an increase in AUC and specificity. Combinations of FibroTest with APRI and/or FIB-4, and FIB-4 with APRI were optimal for the evaluation of liver fibrosis. Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further. © Copyright 2018 by The Turkish Society of Gastroenterology.

Published
2018

5. liver fibrosis in chronic hepatitis C infection: A multicenter

Author

Koksal, I, Yilmaz, G, Parlak, M, Demirdal, T, Kinikli, S, Candan, M, Kaya, A, Akhan, S, Aydogdu, O, Turgut, H, Gurbuz, Y, Dagli, O, Gokal, AA, Guner, R, Kuruuzum, Z, Tarakci, H, Beslen, N, Erdogan, S, and Ozdener, F

Subjects
Chronic hepatitis C infection, liver fibrosis, FibroTest, APRI, Forns, index, Fib-4, non-invasive serum biomarkers
Abstract

Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold standard for assessment of fibrosis but this procedure is an invasive procedure. We aimed to evaluate the diagnostic efficiency of non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients. Materials and Methods: Two hundred and sixteen treatment-naive CHC patients were enrolled from 32 locations across Turkey in this open-labelled, non-interventional prospective observational study. FibroTest (R), aspartate aminotransferase-to-platelet ratio index(A-PRI), aspartate aminotransferase and alanine aminotransferase ratio (AAR), fibrosis index based on four factors (FIB-4), Age-platelet(AP) index and Forns index were measured and compared with Metavir scores got from liver biopsies. Results: Data from 182 patients with baseline liver biopsy were suitable for analysis. One hundred and twenty patients (65.9%) had F0-F1 fibrosis and 62 patients (34.1%) had F2-F4 fibrosis. APRI 0.732 area under the curve(AUC) indicated advanced fibrosis with 69% sensitivity and 77% specificity. FIB-4 0.732 AUC and FibroTest 0.715 AUC indicated advanced fibrosis with 69% and 78.4% sensitivity, and 75% and 71.4% specificity, respectively. The combined use of tests also led to an increase in AUC and specificity. Combinations of FibroTest with APRI and/or FIB-4, and FIB-4 with APRI were optimal for the evaluation of liver fibrosis. Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results